Table 1.

Clinical characteristics

	Dilated cardiomyopathy n=60	Control subjects n=30	P-value
Age, years, Med (range)	57 (23–74)	59 (28–73)	0·59
Male, (%)	48 (80)	17 (57)	0·02
BMI, kg/m2, Med	27·7 (24·9–30·8)	26·2 (24·1–29·1)	0·21
LVEF, %, Med (range)	32 (13–50)	67 (54–79)	<0·001
LVEF = 40–50%	11 (18)	0
LVEF = 31–39%	25 (42)	0
LVEF = 25–30%	16 (27)	0
LVEF = < 25%	8 (13)	0
NYHA classification			0·043
NYHA I	25 (42)	15 (50)
NYHA II	24 (40)	15 (50)
NYHA III	11 (18)	0
Left bundle branch block (>120msec)	27 (45)	0	<0·001
Hypertension	52 (87)	23 (77)	0·23
Diabtes mellitus	14 (23)	2 (7)	0·051
Renal dysfunction	17 (28)	0	0·001
Stroke	6 (10)	1 (3)	0·27
Syncope	8 (13)	1 (3)	0·14
Non-sustained VT	12 (24)	1 (3)	0·84
Medication
Beta-blocker	54 (90)	18 (60)	<0·001
Sotalol	1 (2)	2 (7)	0·21
Amiodarone	10 (17)	0	0·018
ACE inhibitors	51 (85)	11 (37)	<0·001
Angiotensin receptor blockers	22 (37)	8 (27)	0·34
Diuretics	38 (63)	7 (23)	<0·001
Follow-up, years, Med (mean±SD)	1·8 6·6 6·8 (4·8±2·6)	8·7 8·7 8·7 (8·5±1)	<0·001
ICD implanted	10 (17)	0	0·018
CRT-P / -D implanted	7 (12) / 4 (7)*	0	<0·001
ICD therapy	7 (12)	0	0·036

Data are n (%), unless otherwise indicated; Med=median (Q1–Q3); test used: Wilxocon test or chi-square test. Renal dysfunction= persistent serum creatinine >1.2mg/dl.

^*4 CRT-D upgrades during follow-up